Motif Bio Presents New Iclaprim Data at IDWeek
Iclaprim safety and efficacy in patients with wound infections in REVIVE Phase 3 trials
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that iclaprim data are being presented at IDWeek being held in San Francisco, CA, USA October 4-7, 2018. The data show that iclaprim was non-inferior to vancomycin in a pooled analysis of a subgroup of patients in the REVIVE Phase 3 trials who had wound infections. The results are being presented in the Novel Agents poster abstract session on October 5th, 12:30 PM - 1:45 PM PT in poster #1338, A Pooled Analysis of Patients with Wound Infections in the Phase 3 REVIVE Trials: Randomized, Double-blind Studies to Evaluate the Safety and Efficacy of Iclaprim Versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections.